AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20046519
Drug: azasetron 10
RxNorm normalized name: Azasetron
DrugBank: Azasetron (DB16837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azasetron 10 mg (group A)
Trial: 6309461
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril once daily
Trial: 6309461
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalapril twice daily
Trial: 31771921
Drug: Recommended Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended Daily Allowance level of protein (0.8 g protein/kg BW)
Trial: 29023803
Drug: Tenofovir (TDF)
RxNorm normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir (TDF) therapy for 384 weeks
Trial: 29023803
Drug: HBeAg decline
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBeAg decline ≥2.2 log10 PEIU/mL at week 24
Trial: 21960535
Drug: Levosimendan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion)
Trial: 11231941
Drug: Rofecoxib, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib, 50 mg once daily for 5 days
Trial: 8614706
Drug: flesinoxan (5-HT1A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flesinoxan (5-HT1A agonist)
Trial: 1002852
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for /s/‐defective children, 1 hour per week for 5 weeks.
Trial: 1002852
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (control group).
Trial: 29471855
Drug: 16 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 sessions of EMDR therapy
Trial: 24637663
Drug: Chronic menthol
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic menthol capsule treatment
Trial: 23123230
Drug: Flurizan (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurizan (a γ‐secretase modulator)
Trial: 19105409
Drug: Mildronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildronate (1 g/day) with basic anti‐diabetic treatment and alpha‐lipoic acid for 3 months
Trial: 8983936
Drug: New tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet formulation of carbamazepine (400 mg single oral dose)
Trial: 27687820
Drug: Solifenacin (5mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5mg, titrated to optimum dose)
Trial: 14738830
Drug: Whitening gel
RxNorm normalized name: HYDROGEN PEROXIDE 2.8 g in 100 g TOPICAL GEL [Luzen Whitening Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitening gel containing 6% hydrogen peroxide
Trial: 11404532
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug therapy (zidovudine 300 mg or 200 mg for body weight <60 kg, lamivudine 150 mg, didanosine 200 mg or 125 mg for body weight <60 kg)
Trial: 11404532
Drug: Double drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double drug therapy
Trial: 11404532
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug therapy
Trial: 9404926
Drug: Low-dose G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose G-CSF (50 microg/m2/day)
Trial: 9404926
Drug: Standard-dose G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose G-CSF (5 microg/kg/day, approximately 200 microg/m2/day)
Trial: 9404926
Drug: Standard-dose G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose G-CSF (5 microg/kg/day)
Trial: 24513849
Drug: 1.4 g
RxNorm normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g XOS
Trial: 24513849
Drug: 2.8 g
RxNorm normalized name: glycerin 2.8 GM per 2.7 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g XOS
Trial: 22809107
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (2,500 Lux) for 1 week
Trial: 18500187
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg/kg in 10 mL 0.9% normal saline
Trial: 18500187
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mL of 0.25%
Trial: 11704073
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of hydrocortisone
Trial: 7958669
Drug: Complete amino
RxNorm normalized name: Complete Amino Acid Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete amino acid solution containing the dipeptide L‐alanyl‐L‐glutamine (20 g/L)
Trial: 20671376
Drug: Other antiplatelet
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiplatelet aggregation drugs
Trial: 11283125
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cytarabine (Ara-C) added to high-dose intravenous methotrexate (MTX)
Trial: 8504271
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE) (Prostin E2, 0.5 mg per tablet)
Trial: 29848422
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (0.5% proparacaine hydrochloride, pledget soaked, applied 3 minutes before surgery)
Trial: 25662557
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (red laser)
Trial: 25662557
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (infrared laser)
Trial: 18572153
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A (100, 200, 300, and 400 microg doses, twice daily for a week at each dose)
Trial: 14697809
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and basiliximab (steroid-free)
Trial: 14697809
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and steroids (historical control)
Trial: 16181747
Drug: Amoxicillin (AMX)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMX)
Trial: 24285642
Drug: Successful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatment of insomnia
Trial: 22700830
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV-7) administered to all residents in 11 villages.
Trial: 20399326
Drug: Exenatide +
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide + lifestyle modification program (5 microg twice daily, increased to 10 microg after 4 weeks)
Trial: 17943589
Drug: Intravenous patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient‐controlled analgesia (IV‐PCA)
Trial: 17943589
Drug: Intramuscular analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular analgesics (meperidine)
Trial: 11991427
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with reassurance, a well-fitted brassiere, caffeine reduction, and primrose oil
Trial: 11991427
Drug: Medications such
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications such as danazol, bromocriptine, and tamoxifen
Trial: 11991427
Drug: Future studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Future studies should include selective-serotonin reuptake inhibitors and primrose oil
Trial: 22216503
Drug: Bumetanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1 mg)
Trial: 7287241
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (250 mg)
Trial: 6756707
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg daily/6 days)
Trial: 24115138
Drug: Cholecalciferol 1600
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Trial: 18095197
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg gabapentin
Trial: 21493417
Drug: Midazolam 50
RxNorm normalized name: midazolam 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 50 µg/kg
Trial: 21493417
Drug: Midazolam 75
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 75 µg/kg
Trial: 21493417
Drug: Midazolam 50
RxNorm normalized name: midazolam 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 50 µg/kg and Midazolam 75 µg/kg
Trial: 19458163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients naïve to both drugs
Trial: 28249119
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL blueberry concentrate providing 387 mg anthocyanidins
Trial: 25129453
Drug: Treatment buddying
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment buddying
Trial: 25129453
Drug: Treatment buddying
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment buddying with PAS
Trial: 21200360
Drug: MenACWY-DT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-DT vaccine (Control)
Trial: 22704725
Drug: MenACWY-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT vaccine
Trial: 18086463
Drug: PUFA supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA supplement (eicosapentanoic acid (EPA) plus docosahexanoic acid (DHA), 2.2 mg/day in a 3:2 ratio)
Trial: 10673513
Drug: Doxorubicin (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (second-line therapy after cross-over)
Trial: 6548867
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy for 1 year (group A)
Trial: 6548867
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy for 1 year and postoperative radiation therapy (group B)
Trial: 29504415
Drug: Naloxegol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol (12.5 and/or 25 mg)
Trial: 29504415
Drug: Naloxegol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol (all doses)
Trial: 25118129
Drug: Counseling for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling for the family (one counseling session from a nurse) plus treatment-as-usual for the patient
Trial: 25118129
Drug: Family psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family psychoeducation (four, two-hour biweekly multifamily psychoeducation sessions) plus treatment-as-usual for the patient (consultation by physicians)
Trial: 23571150
Drug: High-dose infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusional 5-fluorouracil (HD-FU)
Trial: 12821733
Drug: IV ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days
Trial: 9375752
Drug: G-CSF (0.3-3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (0.3-3.0 microg/kg/d, s.c.) and epo (60-300 U/kg/d, s.c.) for at least 10 weeks
Trial: 9375752
Drug: G-CSF plus
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF plus epo
Trial: 9375752
Drug: Predictive scoring
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive scoring system based on pre-treatment serum epo levels and RBC transfusion need
Trial: 30980122
Drug: Tiopronin or
RxNorm normalized name: tiopronin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin or D-penicillamine at 2 g/day
Trial: 30980122
Drug: Tiopronin or
RxNorm normalized name: tiopronin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin or D-penicillamine at 3 g/day
Trial: 30284393
Drug: Nepafenac (Nevanac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac (Nevanac, 1 mg/ml) for 3 weeks
Trial: 22136324
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro with recombinant human hyaluronidase (rHuPH20)
Trial: 18511355
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day vitamin K1
Trial: 11686812
Drug: Powered toothbrush
RxNorm normalized name: Pro Clean Spinbrush Powered Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered toothbrush (Braun Oral‐B 3D Plaque Remover)
Trial: 7929695
Drug: High-dose IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-1 alpha (3.0 micrograms/m2/day)
Trial: 7929695
Drug: Low-dose IL-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-1 alpha (0.1, 0.3, or 1.0 microgram/m2/day)
Trial: 7929695
Drug: High-dose IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-1 alpha
Trial: 7929695
Drug: Low-dose IL-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-1 alpha
Trial: 29635419
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine in children with non-BCG-vaccinated mothers
Trial: 29635419
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine in children born by cesarean section
Trial: 26923690
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatment and exercise therapy
Trial: 22034523
Drug: Peppermint spirits
RxNorm normalized name: Peppermint
DrugBank: Peppermint (DB10984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint spirits inhalation
Trial: 19733206
Drug: 0.61% green
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.61% green tea extract solution (OM24, 100% Camellia Sinensis leaf extract, catechin concentration: 30+/‐3%, pH 7.0, Omnimedica, Switzerland)
Trial: 11907288
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg daily for six weeks)
Trial: 1495854
Drug: Exogenous surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous surfactant therapy
Trial: 2404097
Drug: Sham (air)
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (air) therapy
Trial: 27432356
Drug: COBRA Classic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COBRA Classic (MTX + sulfasalazine + prednisone step-down from 60 mg)
Trial: 27432356
Drug: COBRA Slim
RxNorm normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA Slim (MTX + prednisone step-down from 30 mg) high risk
Trial: 27432356
Drug: COBRA Avant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COBRA Avant Garde (MTX + leflunomide + prednisone step-down from 30 mg)
Trial: 21867532
Drug: Neuromuscular Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular Electrical Stimulation (NMES) Therapy
Trial: 19152514
Drug: 20% ALA-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% ALA-based photodynamic therapy (PDT) applied for 4 hours, followed by excimer-dye laser exposure at 630 nm at a dose of 50 J/cm² three times at 7-day intervals.
Trial: 9571555
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous indomethacin
Trial: 22289547
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml normal saline
Trial: 22289547
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml normal saline containing adrenaline (5 μg/ml)
Trial: 16672731
Drug: Three-factor solution
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-factor solution (somatic, affective, and cognitive)
Trial: 7956269
Drug: Good description
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good description (G) of assignment methods
Trial: 30643079
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg dual therapy
Trial: 26446728
Drug: Drug-Coated Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloon Angioplasty (DCBA)
Trial: 17020889
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (sirolimus or paclitaxel-eluting)
Trial: 22675955
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg
Trial: 25771759
Drug: Forearm tourniquet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm tourniquet IVRA with 10 mL of 0.5% lidocaine and 30 mL of 0.25% lidocaine
Trial: 25771759
Drug: Conventional upper
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional upper arm tourniquet IVRA with 40 mL of 0.5% lidocaine
Trial: 24210183
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy followed by delayed nephrectomy
Trial: 11324215
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded single-tooth implants in fresh extraction sites
Trial: 11324215
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded single-tooth implants in healed sites
Trial: 28600913
Drug: Once-daily SMBG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily SMBG
Trial: 28600913
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including no SMBG, once-daily SMBG, and once-daily SMBG with messaging)
Trial: 23589107
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with HLA-A*0201-modified tumor peptides and low-dose cyclophosphamide (CTX) and low-dose interleukin-2 (IL-2)
Trial: 16469146
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk with L. johnsonii La1
Trial: 16469146
Drug: Placebo (fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (fermented milk without L. johnsonii La1)
Trial: 9140210
Drug: Vanadyl sulphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanadyl sulphate treatment group
Trial: 25854021
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with ultraviolet therapy
Trial: 25854021
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group (intravenous acyclovir, muscular cobamamide, topical acyclovir, TDP radiation)
Trial: 17429101
Drug: No Gap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Gap (immediate treatment)
Trial: 15552889
Drug: Protease inhibitors,
RxNorm normalized name: Protease inhibitors, direct acting antivirals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors, H2 receptor antagonists, and somatostatin analogues
Trial: 24802242
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 NRTI plus protease inhibitor)
Trial: 6092990
Drug: Methylprednisolone (45‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (45‐60 mg/M2)